Major clinical trials for CD19 CAR T cells
| Study . | n . | Median age (range), y . | CR,* % . | MRD-CR, % . | Relapse, % . | EFS . | OS . |
|---|---|---|---|---|---|---|---|
| University of Pennsylvania/Children’s Hospital of Philadelphia13 | 30 | 14 (5-60) | 90 | 88 | 26 | 6-mo = 67% | 6-mo = 78% |
| Memorial Sloan Kettering Cancer Center14 | 53 | 44 (23-74) | 83 | 67 | 57 | Median = 6.1 mo | Median = 12.9 mo |
| ELIANA trial15 | 75 | 11 (3-23) | 81 | 81 | 36 | 12-mo = 50% | 12-mo = 76% |
| National Cancer Institute16 | 21 | 13 (1-30) | 67 | 86 | 14 | 5-mo = 79%† | 10-mo = 52% |
| Seattle Children’s Hospital17 | 45 | 12 (1-25) | 93 | 100 | 45 | 12-mo = 51% | 12-mo = 70% |
| Fred Hutchinson Cancer Research Center18 | 53 | 39 (20-76) | 85 | 85 | 49 | Median = 7.6 mo | Median = 20 mo |
| Hebei Yanda Lu Daopei Hospital19 | 51 | 11 (3-68)‡ | 90 | 88 | 24 | NR§ | NR§ |
| 24 (2-44)¶ | |||||||
| City of Hope21 | 13 | 33 (24-72) | 100 | 91 | NR | NR | NR |
| CARPALL trial20 | 14 | 9 (1-19) | 86 | 86 | 50 | 12-mo = 46% | 12-mo = 63% |
| Study . | n . | Median age (range), y . | CR,* % . | MRD-CR, % . | Relapse, % . | EFS . | OS . |
|---|---|---|---|---|---|---|---|
| University of Pennsylvania/Children’s Hospital of Philadelphia13 | 30 | 14 (5-60) | 90 | 88 | 26 | 6-mo = 67% | 6-mo = 78% |
| Memorial Sloan Kettering Cancer Center14 | 53 | 44 (23-74) | 83 | 67 | 57 | Median = 6.1 mo | Median = 12.9 mo |
| ELIANA trial15 | 75 | 11 (3-23) | 81 | 81 | 36 | 12-mo = 50% | 12-mo = 76% |
| National Cancer Institute16 | 21 | 13 (1-30) | 67 | 86 | 14 | 5-mo = 79%† | 10-mo = 52% |
| Seattle Children’s Hospital17 | 45 | 12 (1-25) | 93 | 100 | 45 | 12-mo = 51% | 12-mo = 70% |
| Fred Hutchinson Cancer Research Center18 | 53 | 39 (20-76) | 85 | 85 | 49 | Median = 7.6 mo | Median = 20 mo |
| Hebei Yanda Lu Daopei Hospital19 | 51 | 11 (3-68)‡ | 90 | 88 | 24 | NR§ | NR§ |
| 24 (2-44)¶ | |||||||
| City of Hope21 | 13 | 33 (24-72) | 100 | 91 | NR | NR | NR |
| CARPALL trial20 | 14 | 9 (1-19) | 86 | 86 | 50 | 12-mo = 46% | 12-mo = 63% |
*CR (complete remission) is inclusive of CR with count recovery, as well as CR with incomplete hematologic recovery and CR with incomplete count recovery.
LFS (leukemia-free survival).
Patients with r/r ALL.
After HSCT: 6-month LFS, 81.3%; 6-month relapse rate, 11.9%.
Patients treated for MRD positive disease.